Junan Li
Overview
Explore the profile of Junan Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taheri H, Li Y, Huang K, Ahmed E, Jin Y, Drabison T, et al.
Cancer Res Commun
. 2025 Mar;
PMID: 40062557
Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is...
2.
Jin Y, Basu S, Feng M, Ning Y, Munasinghe I, Joachim A, et al.
Nat Commun
. 2024 Nov;
15(1):9409.
PMID: 39482311
Visceral leishmaniasis is a life-threatening parasitic disease, but current antileishmanial drugs have severe drawbacks. Antifungal azoles inhibit the activity of cytochrome P450 (CYP) 51 enzymes which are responsible for removing...
3.
Emptage R, Lovatt B, Sloan C, Li J, Downing M, Summers K
Front Public Health
. 2024 Oct;
12:1441904.
PMID: 39351028
Objective: Increased medication misuse over the last two decades has prompted extensive discussion about the lack of evidence-based and evidence-informed prevention education programs targeting the topic. As older adults are...
4.
La Rosa C, Sharma P, Junaid Dar M, Jin Y, Qin L, Roy A, et al.
Bioorg Med Chem
. 2024 Sep;
113:117907.
PMID: 39288704
CYP5122A1, an enzyme involved in sterol biosynthesis in Leishmania, was recently characterized as a sterol C4-methyl oxidase. Screening of a library of compounds against CYP5122A1 and CYP51 from Leishmania resulted...
5.
Li J, Poi M
Anticancer Res
. 2024 Aug;
44(9):3771-3776.
PMID: 39197892
Background/aim: The tumor suppressor CDKN2C (also designed as p18 or p18) is deleted in approximately 7% to 40% of multiple myeloma (MM) patients, indicative of its potential association with myeloma...
6.
Williams V, Haddad M, Kelley K, Li J, Rodis J
Am J Pharm Educ
. 2024 Aug;
88(9):101257.
PMID: 39127428
Objective: The primary objective of this study was to evaluate the students' choice of activities and perception of a cocurricular program (CCP). Attitude and skill development and areas for program...
7.
Lopez A, Snider M, McFerran A, Holland A, Bagnola A, Mellet J, et al.
J Pharm Pract
. 2024 Jul;
38(1):52-59.
PMID: 39032170
Limited evidence exists regarding pharmacist involvement and impact in inflammatory bowel disease (IBD) interdisciplinary clinic care models. The purpose is to describe pharmacist utilization in an interdisciplinary IBD clinic and...
8.
Feltes A, Combs J, Reynolds M, Conroy M, Lindsey S, Dick M, et al.
Am J Emerg Med
. 2024 Jul;
83:64-68.
PMID: 38968852
Background: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections continue to increase in the United States. Advancement in technology with point-of-care (POC) testing can improve the overall treatment of sexually...
9.
Repas J, Pruchnicki Coyle M, Revelos F, Winhoven M, Li J, Legg J
Am J Pharm Educ
. 2024 Jul;
88(8):100750.
PMID: 38964505
Objective: Medication reconciliation (MedRec) is an essential health care function that is particularly relevant to pharmacists' expertise and a learning opportunity for pharmacy students. Our objective was to assess change...
10.
Lohmann A, Coad L, Barton C, Vulcano D, Li J, Emptage R
Sr Care Pharm
. 2024 Jun;
39(7):267-276.
PMID: 38937889
There is limited research on the impact of fall prevention education for older community-living people led by student pharmacists, which includes a medication review to identify Fall Risk-Increasing Drugs (FRIDs)....